TNX-102 SL
TNX-CY-PA201
Phase 2 small_molecule completed
Quick answer
TNX-102 SL for Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection is a Phase 2 program (small_molecule) at Tonix Pharmaceuticals Holding with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Tonix Pharmaceuticals Holding
- Indication
- Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed